Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus
暂无分享,去创建一个
K. Balakin | G. Aliev | G. Barreto | V. Tarasov | Y. Shtyrlin | A. Spasov | P. Vassiliev | D. Babkov | N. Shtyrlin | A. Iksanova | O. Mayka | M. S. Dzyurkevich
[1] Yongguo Li,et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study , 2016, Drug design, development and therapy.
[2] O. A. Hidalgo,et al. Implication of Green Tea as a Possible Therapeutic Approach for Parkinson Disease. , 2016, CNS & neurological disorders drug targets.
[3] S. Mudaliar,et al. AMG 151 (ARRY‐403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes , 2016, Diabetes, obesity & metabolism.
[4] J. Zhi,et al. Effects of piragliatin, a glucokinase activator, on fasting and postprandial plasma glucose in patients with type 2 diabetes mellitus , 2016, Journal of clinical pharmacology.
[5] G. Aliev,et al. Approaches for the Development of Drugs for Treatment of Obesity and Metabolic Syndrome. , 2016, Current pharmaceutical design.
[6] R. González-Reyes,et al. Alterations in Glucose Metabolism on Cognition: A Possible Link Between Diabetes and Dementia. , 2016, Current pharmaceutical design.
[7] W. S. Denney,et al. Two dose‐ranging studies with PF‐04937319, a systemic partial activator of glucokinase, as add‐on therapy to metformin in adults with type 2 diabetes , 2015, Diabetes, obesity & metabolism.
[8] R. Radhakrishnan,et al. An updated compact review on diabetes and moleculer target of oral hypoglycemic agents , 2014 .
[9] L. P. Sysoeva,et al. Synthesis and antibacterial activity of novel phosphonium salts on the basis of pyridoxine. , 2013, Bioorganic & medicinal chemistry.
[10] S. L. Gwaltney,et al. Design, synthesis and SAR of novel glucokinase activators. , 2013, Bioorganic & medicinal chemistry letters.
[11] Y. Terauchi,et al. [Glucokinase activators]. , 2012, Nihon rinsho. Japanese journal of clinical medicine.
[12] C. Stanley,et al. Mutational analysis of allosteric activation and inhibition of glucokinase. , 2011, The Biochemical journal.
[13] D. Porte,et al. Glucokinase activators (GKAs) promise a new pharmacotherapy for diabetics , 2010, F1000 medicine reports.
[14] L. P. Sysoeva,et al. Theoretical and experimental study on cyclic 6-methyl-2,3,4-tris(hydroxymethyl)pyridin-5-ol acetonides , 2010 .
[15] Arthur J. Olson,et al. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..
[16] L. P. Sysoeva,et al. New synthetic method for 2,3,4-tris(hydroxymethyl)- 6-methylpyridin-5-ol , 2009 .
[17] L. Agius. Glucokinase and molecular aspects of liver glycogen metabolism. , 2008, The Biochemical journal.
[18] G. Fisher,et al. Isolation and culture of skin fibroblasts. , 2005, Methods in molecular medicine.
[19] J. Grippo,et al. Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy , 2003, Science.